NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Shares of Super Micro Computer extend last week’s sharp gains, Snowflake stock is upgraded, and MicroStrategy falls after buying more Bitcoin.

U.S. stocks climbed Monday as investors cheered President-elect Donald Trump’s choice for Treasury secretary ahead of a ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $26.48 which represents a decrease of $-5.70 or -17.71% from the prior close of $32.18. The stock opened at $31.36 and ...

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示 ，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。 该 ...

Cassava Sciences (SAVA) announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet ...

Cassava Sciences Inc. faced a major setback as its Alzheimer's drug, simufilam, failed to meet critical endpoints in a Phase ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was ...

Cassava Sciences’ stock plummets 85% after its Alzheimer’s treatment trial fails. Investigations and regulatory scrutiny add ...